Serina Therapeutics (NYSEAMERICAN:SER) Releases Quarterly Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) released its quarterly earnings data on Wednesday. The company reported ($0.31) earnings per share (EPS) for the quarter, FiscalAI reports.

Serina Therapeutics Stock Up 24.7%

SER stock traded up $0.60 during mid-day trading on Wednesday, hitting $3.03. The stock had a trading volume of 3,221,545 shares, compared to its average volume of 4,865,929. Serina Therapeutics has a 1-year low of $1.22 and a 1-year high of $7.92. The business’s fifty day moving average price is $2.11. The stock has a market cap of $32.69 million, a PE ratio of -1.62 and a beta of 1.25.

Insider Activity

In related news, insider Randall Moreadith sold 39,000 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.50, for a total value of $97,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders sold 63,000 shares of company stock worth $172,365. 17.00% of the stock is owned by insiders.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.